{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:54:50Z","timestamp":1790963690752,"version":"4.1.0"},"reference-count":28,"publisher":"Impact Journals, LLC","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,18]]},"DOI":"10.18632\/oncotarget.15814","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T03:32:34Z","timestamp":1488511954000},"page":"26744-26754","source":"Crossref","is-referenced-by-count":58,"title":["Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma"],"prefix":"10.18632","volume":"8","author":[{"given":"Shingo","family":"Inaguma","sequence":"first","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA"},{"name":"Department of Pathology, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Lasota","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Onda","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Czapiewski","sequence":"additional","affiliation":[{"name":"Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland"},{"name":"Department of Pathology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Langfort","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Rys","sequence":"additional","affiliation":[{"name":"Department of Tumor Pathology, Centre of Oncology, Maria Sklodowska-Curie Memorial Institute, Krakow Branch, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Szpor","sequence":"additional","affiliation":[{"name":"Department of Pathomorphology, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Waloszczyk","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Pathology, Zdunomed, Szczecin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Oko\u0144","sequence":"additional","affiliation":[{"name":"Department of Pathomorphology, Jagiellonian University, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Biernat","sequence":"additional","affiliation":[{"name":"Department of Pathomorphology, Medical University of Gdansk, Gdansk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Pathology, Aichi Medical University School of Medicine, Nagakute, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Schrump","sequence":"additional","affiliation":[{"name":"Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[{"name":"Thoracic and GI Oncology Branch, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Miettinen","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,1]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Pastan","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Pastan","year":"2000","journal-title":"Mol Cell Biol"},{"key":"3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00000478-199203000-00006","article-title":"Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma","volume":"16","author":"Willingham","year":"1992","journal-title":"Am J Surg Pathol"},{"key":"4","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/01.pai.00000141545.36485.d6","article-title":"Localization of mesothelin in epithelial ovarian cancer","volume":"13","author":"Willingham","year":"2005","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"5","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1309\/F1B64CL7H8VJKEAF","article-title":"Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis","volume":"124","author":"Brackett","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000478-200302000-00002","article-title":"Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura","volume":"27","author":"Sarlomo-Rikala","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Adusumilli","year":"2014","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"11694","DOI":"10.18632\/oncotarget.3429","article-title":"High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis","volume":"6","author":"Hassan","year":"2015","journal-title":"Oncotarget"},{"key":"10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/bjc.2012.235","article-title":"Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer","volume":"107","author":"Taketomi","year":"2012","journal-title":"Br J Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Patankar","year":"2006","journal-title":"Mol Cancer"},{"key":"12","first-page":"20","article-title":"Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin","volume":"7","author":"Iacobuzio-Donahue","year":"2007","journal-title":"Cancer Immun"},{"key":"13","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1074\/jbc.M806776200","article-title":"A binding domain on mesothelin for CA125\/MUC16","volume":"284","author":"Ho","year":"2009","journal-title":"J Biol Chem"},{"key":"14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Yao","year":"2011","journal-title":"Carcinogenesis"},{"key":"15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/BJ20082196","article-title":"Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway","volume":"424","author":"Cheng","year":"2009","journal-title":"Biochem J"},{"key":"16","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Adusumilli","year":"2012","journal-title":"Clin Cancer Res"},{"key":"17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1158\/1535-7163.MCT-11-0454","article-title":"Mesothelin-targeted agents in clinical trials and in preclinical development","volume":"11","author":"Hassan","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"18","doi-asserted-by":"crossref","first-page":"7026","DOI":"10.1200\/jco.2011.29.15_suppl.7026","article-title":"Antitumor activity of SS1P with pemetrexed and cisplatin for front-line treatment of pleural mesothelioma and utility of serum mesothelin as a marker of tumor response","volume":"29","author":"Pastan","year":"2011","journal-title":"J Clin Oncol"},{"key":"19","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1200\/jco.2011.29.15_suppl.7086","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in malignant pleural mesothelioma","volume":"29","author":"Van Meerbeeck","year":"2011","journal-title":"J Clin Oncol"},{"key":"20","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/1471-2407-14-674","article-title":"A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice","volume":"14","author":"Popat","year":"2014","journal-title":"BMC Cancer"},{"key":"21","article-title":"Efficacy of Anti-Mesothelin Immunotoxin RG7787 plus nab-Paclitaxel against Mesothelioma Patient Derived Xenografts and Mesothelin as a Biomarker of Tumor Response","author":"Hassan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"22","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1158\/1078-0432.CCR-05-0578","article-title":"New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA","volume":"11","author":"Pastan","year":"2005","journal-title":"Clin Cancer Res"},{"key":"23","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Pastan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/PAI.0b013e318245c82f","article-title":"A simple method for generating multitissue blocks without special equipment","volume":"20","author":"Miettinen","year":"2012","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","article-title":"Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients","volume":"97","author":"Hida","year":"2006","journal-title":"Cancer Sci"},{"key":"26","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/PAS.0000000000000229","article-title":"Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach","volume":"38","author":"Miettinen","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"27","article-title":"Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors","author":"Miettinen","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T14:33:07Z","timestamp":1596724387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,1]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2017,4,18]]}},"alternative-id":["15814","28460459"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15814","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,1]]}}}